Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,405.20
(
-2.38%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
106.89
(
0.00%
)
Bitcoin
66,852.18
(
0.77%
)
News Focus
News Focus
Post# of 257301
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122817
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 188317

Wednesday, 09/28/2016 4:23:12 PM

Wednesday, September 28, 2016 4:23:12 PM

Post# of 257301
ENTA starts phase-1 trial of NASH compound, EDP-305:

http://finance.yahoo.com/news/enanta-pharmaceuticals-initiates-phase-1-201200159.html

EDP-305 is an FXR agonist—the same drug class as ICPT's OCA and GILD's GS-9674 (acquired from PFNX in 2015: #msg-109653984).

ENTA has asserted that EDP-305 is substantially more potent than ICPT's OCA—see slides 24, 26, &27 at http://jpmorgan.metameetings.com/confbook/healthcare16/stash/slides/19782/confbook_slideshow.php .

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today